Circulating estrogen metabolites and risk of breast cancer in postmenopausal women

Alan A. Arslan, Karen L. Koenig, Per Lenner, Yelena Afanasyeva, Roy E. Shore, Yu Chen, Eva Lundin, Paolo Toniolo, Göran Hallmans, Anne Zeleniuch-Jacquotte

Research output: Contribution to journalArticle

Abstract

Background: It has been hypothesized that predominance of the 2-hydroxylation estrogen metabolism pathway over the 16a-hydroxylation pathway may be inversely associated with breast cancer risk. Methods: We examined the associations of invasive breast cancer risk with circulating 2-hydroxyestrone (2- OHE1), 16a-hydroxyestrone (16a-OHE1), and the 2-OHE1:16a-OHE1 ratio in a case-control study of postmenopausal women nested within two prospective cohorts: the New York University Women's Health Study (NYUWHS) and the Northern Sweden Mammary Screening Cohort (NSMSC), with adjustment for circulating levels of estrone, and additional analyses by tumor estrogen receptor (ER) status. Levels of 2-OHE1 and 16a- OHE1 were measured using ESTRAMET 2/16 assay in stored serum or plasma samples from 499 incident breast cancer cases and 499 controls, who were matched on cohort, age, and date of blood donation. Results: Overall, no significant associations were observed between breast cancer risk and circulating levels of 2-OHE1, 16a-OHE1, or their ratio in either cohort and in combined analyses. For 2-OHE1, there was evidence of heterogeneity by ER status in models adjusting for estrone (P±0.03).Weobserved a protective association of 2-OHE1 with ER+ breast cancer [multivariate-adjusted OR for a doubling of 2-OHE1, 0.67 (95% confidence interval [CI], 0.48-0.94; P = 0.02)]. Conclusions: In this study, higher levels of 2-OHE1 were associated with reduced risk of ER+ breast cancer in postmenopausal women after adjustment for circulating estrone. Impact: These results suggest that taking into account the levels of parent estrogens and ER status is important in studies of estrogen metabolites and breast cancer.

Original languageEnglish (US)
Pages (from-to)1290-1297
Number of pages8
JournalCancer Epidemiology Biomarkers and Prevention
Volume23
Issue number7
DOIs
StatePublished - 2014

Fingerprint

Estrogens
Breast Neoplasms
Estrogen Receptors
Estrone
Hydroxylation
Hydroxyestrones
Women's Health
Blood Donors
Sweden
Case-Control Studies
Breast
Confidence Intervals
Serum
Neoplasms

ASJC Scopus subject areas

  • Epidemiology
  • Oncology
  • Medicine(all)

Cite this

Arslan, A. A., Koenig, K. L., Lenner, P., Afanasyeva, Y., Shore, R. E., Chen, Y., ... Zeleniuch-Jacquotte, A. (2014). Circulating estrogen metabolites and risk of breast cancer in postmenopausal women. Cancer Epidemiology Biomarkers and Prevention, 23(7), 1290-1297. https://doi.org/10.1158/1055-9965.EPI-14-0009

Circulating estrogen metabolites and risk of breast cancer in postmenopausal women. / Arslan, Alan A.; Koenig, Karen L.; Lenner, Per; Afanasyeva, Yelena; Shore, Roy E.; Chen, Yu; Lundin, Eva; Toniolo, Paolo; Hallmans, Göran; Zeleniuch-Jacquotte, Anne.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 23, No. 7, 2014, p. 1290-1297.

Research output: Contribution to journalArticle

Arslan, AA, Koenig, KL, Lenner, P, Afanasyeva, Y, Shore, RE, Chen, Y, Lundin, E, Toniolo, P, Hallmans, G & Zeleniuch-Jacquotte, A 2014, 'Circulating estrogen metabolites and risk of breast cancer in postmenopausal women', Cancer Epidemiology Biomarkers and Prevention, vol. 23, no. 7, pp. 1290-1297. https://doi.org/10.1158/1055-9965.EPI-14-0009
Arslan, Alan A. ; Koenig, Karen L. ; Lenner, Per ; Afanasyeva, Yelena ; Shore, Roy E. ; Chen, Yu ; Lundin, Eva ; Toniolo, Paolo ; Hallmans, Göran ; Zeleniuch-Jacquotte, Anne. / Circulating estrogen metabolites and risk of breast cancer in postmenopausal women. In: Cancer Epidemiology Biomarkers and Prevention. 2014 ; Vol. 23, No. 7. pp. 1290-1297.
@article{bd512d5012c54cb39290f6e7f204560d,
title = "Circulating estrogen metabolites and risk of breast cancer in postmenopausal women",
abstract = "Background: It has been hypothesized that predominance of the 2-hydroxylation estrogen metabolism pathway over the 16a-hydroxylation pathway may be inversely associated with breast cancer risk. Methods: We examined the associations of invasive breast cancer risk with circulating 2-hydroxyestrone (2- OHE1), 16a-hydroxyestrone (16a-OHE1), and the 2-OHE1:16a-OHE1 ratio in a case-control study of postmenopausal women nested within two prospective cohorts: the New York University Women's Health Study (NYUWHS) and the Northern Sweden Mammary Screening Cohort (NSMSC), with adjustment for circulating levels of estrone, and additional analyses by tumor estrogen receptor (ER) status. Levels of 2-OHE1 and 16a- OHE1 were measured using ESTRAMET 2/16 assay in stored serum or plasma samples from 499 incident breast cancer cases and 499 controls, who were matched on cohort, age, and date of blood donation. Results: Overall, no significant associations were observed between breast cancer risk and circulating levels of 2-OHE1, 16a-OHE1, or their ratio in either cohort and in combined analyses. For 2-OHE1, there was evidence of heterogeneity by ER status in models adjusting for estrone (P±0.03).Weobserved a protective association of 2-OHE1 with ER+ breast cancer [multivariate-adjusted OR for a doubling of 2-OHE1, 0.67 (95{\%} confidence interval [CI], 0.48-0.94; P = 0.02)]. Conclusions: In this study, higher levels of 2-OHE1 were associated with reduced risk of ER+ breast cancer in postmenopausal women after adjustment for circulating estrone. Impact: These results suggest that taking into account the levels of parent estrogens and ER status is important in studies of estrogen metabolites and breast cancer.",
author = "Arslan, {Alan A.} and Koenig, {Karen L.} and Per Lenner and Yelena Afanasyeva and Shore, {Roy E.} and Yu Chen and Eva Lundin and Paolo Toniolo and G{\"o}ran Hallmans and Anne Zeleniuch-Jacquotte",
year = "2014",
doi = "10.1158/1055-9965.EPI-14-0009",
language = "English (US)",
volume = "23",
pages = "1290--1297",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Circulating estrogen metabolites and risk of breast cancer in postmenopausal women

AU - Arslan, Alan A.

AU - Koenig, Karen L.

AU - Lenner, Per

AU - Afanasyeva, Yelena

AU - Shore, Roy E.

AU - Chen, Yu

AU - Lundin, Eva

AU - Toniolo, Paolo

AU - Hallmans, Göran

AU - Zeleniuch-Jacquotte, Anne

PY - 2014

Y1 - 2014

N2 - Background: It has been hypothesized that predominance of the 2-hydroxylation estrogen metabolism pathway over the 16a-hydroxylation pathway may be inversely associated with breast cancer risk. Methods: We examined the associations of invasive breast cancer risk with circulating 2-hydroxyestrone (2- OHE1), 16a-hydroxyestrone (16a-OHE1), and the 2-OHE1:16a-OHE1 ratio in a case-control study of postmenopausal women nested within two prospective cohorts: the New York University Women's Health Study (NYUWHS) and the Northern Sweden Mammary Screening Cohort (NSMSC), with adjustment for circulating levels of estrone, and additional analyses by tumor estrogen receptor (ER) status. Levels of 2-OHE1 and 16a- OHE1 were measured using ESTRAMET 2/16 assay in stored serum or plasma samples from 499 incident breast cancer cases and 499 controls, who were matched on cohort, age, and date of blood donation. Results: Overall, no significant associations were observed between breast cancer risk and circulating levels of 2-OHE1, 16a-OHE1, or their ratio in either cohort and in combined analyses. For 2-OHE1, there was evidence of heterogeneity by ER status in models adjusting for estrone (P±0.03).Weobserved a protective association of 2-OHE1 with ER+ breast cancer [multivariate-adjusted OR for a doubling of 2-OHE1, 0.67 (95% confidence interval [CI], 0.48-0.94; P = 0.02)]. Conclusions: In this study, higher levels of 2-OHE1 were associated with reduced risk of ER+ breast cancer in postmenopausal women after adjustment for circulating estrone. Impact: These results suggest that taking into account the levels of parent estrogens and ER status is important in studies of estrogen metabolites and breast cancer.

AB - Background: It has been hypothesized that predominance of the 2-hydroxylation estrogen metabolism pathway over the 16a-hydroxylation pathway may be inversely associated with breast cancer risk. Methods: We examined the associations of invasive breast cancer risk with circulating 2-hydroxyestrone (2- OHE1), 16a-hydroxyestrone (16a-OHE1), and the 2-OHE1:16a-OHE1 ratio in a case-control study of postmenopausal women nested within two prospective cohorts: the New York University Women's Health Study (NYUWHS) and the Northern Sweden Mammary Screening Cohort (NSMSC), with adjustment for circulating levels of estrone, and additional analyses by tumor estrogen receptor (ER) status. Levels of 2-OHE1 and 16a- OHE1 were measured using ESTRAMET 2/16 assay in stored serum or plasma samples from 499 incident breast cancer cases and 499 controls, who were matched on cohort, age, and date of blood donation. Results: Overall, no significant associations were observed between breast cancer risk and circulating levels of 2-OHE1, 16a-OHE1, or their ratio in either cohort and in combined analyses. For 2-OHE1, there was evidence of heterogeneity by ER status in models adjusting for estrone (P±0.03).Weobserved a protective association of 2-OHE1 with ER+ breast cancer [multivariate-adjusted OR for a doubling of 2-OHE1, 0.67 (95% confidence interval [CI], 0.48-0.94; P = 0.02)]. Conclusions: In this study, higher levels of 2-OHE1 were associated with reduced risk of ER+ breast cancer in postmenopausal women after adjustment for circulating estrone. Impact: These results suggest that taking into account the levels of parent estrogens and ER status is important in studies of estrogen metabolites and breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84903985341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903985341&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-14-0009

DO - 10.1158/1055-9965.EPI-14-0009

M3 - Article

VL - 23

SP - 1290

EP - 1297

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 7

ER -